Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis-Multivariable Prediction Model Based on Machine Learning.
DAPSA
PsAID
arthritis
disease activity
machine learning
predictive model
psoriatic
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Jan 2023
25 Jan 2023
Historique:
received:
25
11
2022
revised:
10
01
2023
accepted:
20
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
The aim was to identify patient- and disease-related characteristics predicting moderate-to-high disease activity in recent-onset psoriatic arthritis (PsA). We performed a multicenter observational prospective study (2-year follow-up, regular annual visits) in patients aged ≥18 years who fulfilled the CASPAR criteria and had less than 2 years since the onset of symptoms. The moderate-to-high activity of PsA was defined as DAPSA > 14. We trained a logistic regression model and random forest-type and XGBoost machine learning algorithms to analyze the association between the outcome measure and the variables selected in the bivariate analysis. The sample comprised 158 patients. At the first follow-up visit, 20.8% of the patients who attended the clinic had a moderate-to-severe disease. This percentage rose to 21.2% on the second visit. The variables predicting moderate-high activity were the PsAID score, tender joint count, level of physical activity, and sex. The mean values of the measures of validity of the machine learning algorithms were all high, especially sensitivity (98%; 95% CI: 86.89-100.00). PsAID was the most important variable in the prediction algorithms, reinforcing the convenience of its inclusion in daily clinical practice. Strategies that focus on the needs of women with PsA should be considered.
Identifiants
pubmed: 36769579
pii: jcm12030931
doi: 10.3390/jcm12030931
pmc: PMC9917876
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AbbVie (Spain)
ID : N/A
Références
Arthritis Rheum. 1998 Dec;41(12):2263-70
pubmed: 9870884
J Rheumatol. 1993 Dec;20(12):2116-22
pubmed: 8014941
Ann Rheum Dis. 2003 Feb;62(2):127-32
pubmed: 12525381
Clin Exp Rheumatol. 2020 Sep-Oct;38(5):973-977
pubmed: 31969229
Clin Exp Rheumatol. 2020 Jan-Feb;38(1):136-139
pubmed: 31376259
Ann Rheum Dis. 2014 Jun;73(6):1012-9
pubmed: 24790067
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Rheumatol. 2019 Aug;46(8):990-995
pubmed: 30554154
J Rheumatol. 2014 Jun;41(6):1212-7
pubmed: 24882854
Clin Rheumatol. 2021 Apr;40(4):1663-1665
pubmed: 33387093
Ann Rheum Dis. 2016 May;75(5):811-8
pubmed: 26269398
Diabetes Obes Metab. 2013 Sep;15 Suppl 3:51-60
pubmed: 24003921
Med Clin (Barc). 2001 Dec 1;117(18):685-9
pubmed: 11730629
Curr Rheumatol Rep. 2020 May 16;22(6):24
pubmed: 32418006
Curr Rheumatol Rep. 2018 May 12;20(6):35
pubmed: 29754330
Rheumatol Ther. 2020 Sep;7(3):447-456
pubmed: 32495313
Reumatol Clin (Engl Ed). 2019 Sep - Oct;15(5):252-257
pubmed: 30522944
PLoS One. 2020 Jun 17;15(6):e0234556
pubmed: 32555622
Br J Rheumatol. 1998 Jul;37(7):760-5
pubmed: 9714353
Arthritis Res Ther. 2022 Jun 24;24(1):153
pubmed: 35751091
Front Med (Lausanne). 2022 Apr 28;9:891863
pubmed: 35572968
J Rheumatol. 2019 Jul;46(7):710-715
pubmed: 30709957
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Arthritis Res Ther. 2017 Mar 29;19(1):72
pubmed: 28356155
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
Curr Pharm Des. 2016;22(24):3730-48
pubmed: 27000826
Clin Exp Rheumatol. 2023 Jan;41(1):137-144
pubmed: 35699067
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii65-8; discussion ii69-73
pubmed: 15708941
Ann Rheum Dis. 2020 Jun;79(6):700-712
pubmed: 32434812